Piper Jaffray Initiates Coverage on Myriad Pharmaceuticals (MYRX) with an Underweight; Pipeline Lacks Sufficient Data
Tweet Send to a Friend
Piper Jaffray & Co. initiates coverage on Myriad Pharmaceuticals (Nasdaq: MYRX) (Nasdaq: MYRXV) with an Underweight. Price target $3.50.
Piper ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Piper ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
